1	
2	
3	
4	
5	A mixed cross-sectional and case-control study approach to
6	investigate the risk-factors of Noma/Cancrum oris in
7	Ethiopia
8	
9	
10	Heron Gezahegn Gebretsadik ^{1*} , Laurent Cleenewerck de Kiev ²
11 12	 ¹ School of Global Health & Bioethics, Euclid University, Banjul, Gambia ² EUCLID (Euclid University), Bangui, Central African Republic
13	
14	* Corresponding author
15	gezahegn.heron@gmail.com
16	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

17 Abstract

18 Introduction

19 Noma is a polymicrobial gangrenous facial disease affecting people living in the most impoverished areas of low- and middle-income countries. If left untreated, the disease is fatal 20 or else severely disfigure people with the condition. The compromised immune system, poor 21 22 oral hygiene, measle infection, diarrheal disease, inaccessibility to health education and proper medical care, and lack of a balanced diet and good sanitary facilities are found to be 23 24 some of the predisposing factors for the development and progression of the disease. Furthermore, debilitating diseases like malaria and measles were considered as significant 25 26 precursors to Noma.

27 Materials and Method

A mix of cross-sectional and case-control study approaches was conducted to assess the risk factors of Noma in Ethiopia. The raw data of the cases were obtained from Yekatik 12 Hospital, Facing Africa, and the Harar project Ethiopia. Three controls were selected per single case. The Odd ratio (ORs) and Chi-square test were calculated to rule out the statistical significance of the association observed between the factors and the disease.

33 **Results**

A total of 64 cases were selected for the case-control study. Considering the 1:3 case to control ratio, 192 matching controls were identified. Malaria, helminths, measle, diarrheal diseases, and living with domestic animals were found to be risk factors for Noma with a

37 respective p-value < 0.01. Contrarily, the analysis has identified vaccination (p < 0.01) as a
38 protective factor.

39 **Discussion**

Noma/face of poverty is mostly preventable by providing proper nutrition, sanitary and water 40 41 facilities, awareness about the disease, oral health education, and vaccinations. Povertyrelated diseases such as malaria, helminths infection, measle, diarrheal diseases, and 42 unfavorable living conditions were identified to be the risk factor for Noma. As such the 43 44 disease is truly preventable. Prevention of the disease can be achieved through promoting overall awareness of the disease, poverty reduction, improved nutrition, and promotion of 45 exclusive breastfeeding in the first 3-6 months of life. Furthermore, optimum prenatal care, 46 timely immunizations against common childhood diseases, initiating vaccination, and 47 improving the social living conditions are the other preventive mechanisms. Moreover, long-48 49 lasting economic development should be considered to effectively and sustainably prevent the disease. 50

52 Introduction

53 Noma is a rapidly progressive, polymicrobial, opportunistic, gangrenous infection of the 54 mouth, most likely caused by certain kinds of Burulibacterial flora that switch to pathogenic when the host is immunocompromised (1). Alternatively known as Stomatitis gangrenosa or 55 Cancrum oris, the etiology of Noma is infectious, yet unclear as regards the exact causative 56 57 microorganism (2). Due to its primary occurrence in young children living in remote areas of 58 the least developed countries with inadequate health systems and its rapid progression rate 59 and high case fatality, today, Noma is a poorly studied disease, and its cause remains 60 idiopathic (3). Because of the potential involvement of bacteria, the transmissibility of Noma has to be considered, but epidemiological patterns and animal experiments currently do not 61 62 support this possibility (4).

Several potential pathogens were found in abundance in the sites of Noma, which include 63 melaninogenica, Corynebacterium pyogenes, Fusobacterium nucleatum, 64 Prevotella 65 Bacteroides fragilis, Bacillus cereus, Prevotella intermedia, and Fusobacterium necrophorum. Microbial analysis in the early 20th century revealed the presence of spirilliform and fusiform 66 microorganisms in biopsy samples taken from the transitional zone between gangrenous and 67 healthy tissues (5). Later studies reported that Fusobacterium necrophorum, a predominant 68 animal pathogen is the most common microorganism isolated from the disease sites in 69 Nigerian children. It was suggested that Fusobacterium necrophorum could be a trigger 70 organism for noma. This microorganism produces various toxins and has been associated with 71 necrotizing infections in animals, and it may contaminate livestock and potentially infect 72 children (6). 73

On the other hand, a recent study has contradicted the involvement of Fusobacterium necrophorum as an etiologic agent (7). Known periodontal pathogens like aggregatibacter actinomycetemcomitans, capnocytophaga, porphyromonia, and fusobacteria were more prevalent in healthy samples compared to those with Noma (8). The study also identified prevotella intermedia and peptostreptococus to be more clearly associated with Noma (9).

Noma is commonly seen in a population with extreme poverty, severe malnutrition, unsafe drinking water, poor sanitation, poor oral health practices, limited access to high-quality health care, and intrauterine growth retardation (10). Recently, an increased incidence of Noma has been reported in patients with Human Immune deficiency Virus (HIV) infection, cyclic neutropenia, leukemia, Down's syndrome, Burkett's disease, and herpetic stomatitis (11).

Malnutrition is considered to be an important risk factor for Noma (12). In Africa, most of the cases were reported during the dry season when food is scarce, and when the incidence of measles is highest. Measles could also be an important risk factor because of its associated immunosuppression (13).

A retrospective study revealed severe malnutrition, recent respiratory or diarrhoeal syndrome, the number of previous pregnancies in the mother, an altered oral microbiota, and the absence of chickens at home as predictors of Noma (14). Furthermore, lack of maternal care, measles, and malnutrition were reported as risk factors for developing Noma in Nigeria (15) (14).

In general, immunodeficiency disorders, including AIDS, down syndrome, malnutrition,
dehydration, poor oral hygiene, recent orofacial and systemic illness, unsafe drinking water,
poverty, malignancy, and living near domestic animals are reported to be other predisposing

factors (16) (17) (18). The unusual case of Noma in a 32-year-old malnourished HIV-97 seropositive female, within three days, the initial intraoral necrotizing process spread rapidly 98 and caused full circular thickness perforating destruction of the lower lip has shown 99 immunosuppression associated with a high HIV load as an important risk factor in South Africa 100 101 (19). On many occasions, recent debilitating conditions like measles (commonly), herpès 102 simplex, varicella, scarlet fever, malaria, gastroenteritis, tuberculosis, and bronchopneumonia appear to set the stage for the development of Noma (1). Also, 103 104 intrauterine growth retardation, down syndrome, exposure to cytomegalovirus, and premature birth have been considered as predisposing factors for the development of Noma. 105 106 Cases associated with malignancies (e.g., leukemia) are not rare (18).

Mortality used to be a common complication of Noma (20). Only approximately 15% of 107 108 children survive acute Noma. However, with the use of modern antibiotics and better nutrition, the mortality rate has reduced from 90% to 8-10% (21). Most Noma patients have 109 110 difficulty in mastication because of the loss of soft and hard tissues. Severe cosmetic disfigurement can also take place from the resulting scarring and loss of tissue (22). At a later 111 age, these contractures often lead to growth disturbances and result in further facial 112 disfigurement and functional impairment. The psychological impact of surviving Noma can be 113 easily understood; patients reported high psychiatric morbidity after Noma (23). 114

Noma is a truly enigmatic disease and very little epidemiological global data are available (24).
The risk factors of the disease are not also well-understood (25). This explains the extent to
which the disease is neglected (26). Yet, the disease affects poor children among the
disadvantaged societies throughout the world including Ethiopia (27). This study was initiated
to assess the risk factors of Noma in Ethiopia.

120 Materials and Methods

121 Study design

A mix of cross-sectional and case-control study approaches was used to identify the possible risk/predisposing factors that could potentially be associated with the development of Noma in this study. The study matched three controls for each corresponding case in terms of geographic location, gender, and age.

126 Study location and population

The cross-sectional and case-control studies were conducted in different parts of the country, 127 including Addis Ababa depending on the findings of the demographic-geographic data 128 129 obtained from patients' medical records review. All the patients' medical records were obtained from the main offices of the three major Noma treatment centers located in Addis 130 131 Ababa. Cases were patients diagnosed with Noma and treated in Yekatit 12 Hospital, Facing Africa Ethiopia or Harar Project Ethiopia between March 2004 and December 2020. The cases 132 were identified via the cross-sectional study. Controls were individuals that matched to cases 133 by the village of residence, current age (+/- 2 years), and sex. 134

135 **Case and control definitions**

136 **Definition of case**

In this study, cases are individuals who have been diagnosed with Noma in Ethiopia between January 2004 and February 2020. To be ascertained as a case of Noma, an individual should have facial edema, intraoral necrotizing stomatitis, metallic taste, typical halitosis (often considered as pathognomonic), bluish discoloration of the skin, gangrenous demarcation, tissue necrosis, and sloughing. Moreover, three or more of the following should be
considered: a history of malnourishment, a history of poor oral hygiene, a history of poverty,
a history of poor sanitation and living close to domestic animals, and a history of debilitating
and immunocompromising diseases such as measle, tuberculosis, AIDS, leukemia.

145 **Definition of control**

- 146 Controls are individuals who were never diagnosed with Noma. Furthermore, the controls 147 need to be matched to cases by the village of residence, current age (+/- 2 years), and sex.
- 148 Data collection and analysis

149 The investigator needed to review the medical registers of Noma cases for the 2004-2020 period including patients' photos with relevant clinical and demographic information to 150 answer the research questions. A modified case report form (CRF) consisting of demographic 151 and clinical sections was used to collect the relevant demographic and clinical information, 152 respectively (Appendix S1). The demographic section of the CRFs contains the name, gender, 153 154 age, physical address (geographic location), telephone address, and year of admission of the patients. On the other hand, the clinical section of the CRFs primarily subdues the localization 155 of Noma-induced anatomical lesions, medical history, dietary information, vaccination 156 details, living stands, and functional impairments data. 157

Similarly, a questionnaire with a set of questions was used to interview the cases (caregivers or guardians) and controls (caregivers or guardians) to complete the case-control study (Appendix S2). Therefore, the information regarding the possible risk factors for Noma was obtained using a structured written questionnaire and reviewing patients' medical charts. The questionnaire also consisted of demographic and clinical (risk factor) data. Both the CRFs and guestionnaire were made to be valid. The researcher verified the validity of the CRFs and the questionnaire. Furthermore, pre-tests were conducted to assess the validity and reliability of
 the data collection instruments that were used in this case-control study.

166 On the other hand, the contact information of the cases, including patient name, telephone number, and home address, were obtained from the CRFs and used to select neighboring 167 controls. The controls were explored for the necessary demographic and clinical information 168 169 to carry out the case-control study. The data analysis of the case-control study follows the entry of relevant clinical and demographic data of the cases and controls into an excel sheet. 170 171 Descriptive analysis was used to determine the characteristics of cases and controls. The odds ratio (OR) was calculated to rule out the existing association between the possible 172 risk/predisposing factors and the disease. A Chi-square test was carried out to test the 173 statistical significance of the associations observed between the predisposing factors and the 174 condition. 175

176 Ethical consideration

The Addis Ababa Health Bureau has given the necessary in-country ethical clearance. Oral consent was received from all the study participants before starting the interview to complete the questionnaire. The interviewees were fully informed about the study and its purpose, expected risks or benefits from participation, and confidentiality of information. All the information was treated secretly. Moreover, the researcher used patients' initials in the excel sheet.

183 **Results**

184 The case-control study was employed to identify the possible risk factors to develop Noma 185 among the cases. The cases were selected from the medical records obtained from the three

Noma treatment centers (Yekatit 12 Hospital, Facing Africa, and Harar Project). Completeness 186 187 of medical records, availability of pertinent contact information (at least phone number), and age of the patient during admission were the criteria to select the 64 cases. 188 189 Out of the 163 Noma patients who had sought care in the programs between March 2004 and December 2020, 64 were eligible for inclusion in the case-control study. Of these, one 190 191 could not be located for logistical reasons, and the researcher managed to interview the study 192 participant via phone. Thus, the final analysis included 64 Noma cases and 192 controls. All 193 cases and controls were under 41 years old. The age restriction was considered to avoid recall bias. The assumed potential risk factors were living with domestic animals, having diarrheal 194 195 disease, having a helminthic infection, exposure to malaria infection, being inflicted with measle infection, and drinking river (Tables 1-6). 196

197 Table 1. Domestic animals at home (2 x 2 table)

	Cases	Controls	Total
Present	35	43	78
Not-present	29	149	178
Total	64	192	256

198

200 Table 2. Diarrheal disease (2 x 2 table)

	Cases	Controls	Total
Present	35	43	78
Not present	29	149	178
Total	64	192	256

201

202 Table 3. Helminthic infection (2 x 2 table)

	Cases	Controls	Total
Present	31	12	43
Not present	33	180	213
Total	64	192	256

203

204 Table 4. Malaria infection (2 x 2 table)

	Cases	Controls	Total
Present	21	14	35
Not present	43	178	221
Total	64	192	256

205

207 Table 5. Measle infection (2 x 2 table)

	Cases	Controls	Total
Present	13	14	27
Not present	51	178	229
Total	64	192	256

208

209 **Table 6. Drinking river water (2 x 2 table)**

	Cases	Controls	Total
Drinks	15	41	56
Not drink	49	151	200
Total	64	192	256

210

211 On the other hand, vaccination was regarded as a potential protective factor based on the

212 literature review (Table 7).

Table 7. Vaccination (2 x 2 table)

	Cases	Controls	Total
Vaccinated	14	104	118
Non-vaccinated	50	88	138
Total	64	192	256

215

The clinical information obtained from the patients' medical records were the main guiding
principles to consider these as a potential risk and protective factors for Noma. Accordingly,
each potential risk factor and the vaccination as protective factors were assessed for having
a statistically significant association with the occurrence of Noma.
In conclusion, malaria, helminthic and measle infections, living with domestic animals, and

diarrheal diseases are identified to be risk/predisposing factors for the development of Noma.
On the contrary, drinking river water has shown no significant association with the
development of Noma among the cases. On the other hand, vaccination is found to be a
protective factor not to develop Noma among the controls.

Risk/protective factor	Odd ratio (ODs)	Chi-square (χ ²)	p-value
Malaria	6.2	24.37	0.000008
Helminthic infection	14.1	58.11	0.000000001
Measle infection	3.2	7.30	0.007
Diarrheal diseases	4.2	22.10	0.000003
Domestic animals	4.1	22.13	0.000002
River water	1.13	0.03	0.9
vaccination	0.24	21.46	0.000004

226 Table 8. Summary of risk and protective factors

227

228 **Discussion**

229 The vast majority of the Noma cases are living in the most deprived and remote regions of sub-Saharan Africa (28). Historically, Noma was most prevalent in the Noma belt region that 230 extends from Senegal to Ethiopia (5). Studies have shown that in countries where the 231 condition is widespread, risk factors such as malnutrition, debilitating diseases like malaria 232 233 and measles, close residential proximity to livestock are reported (29) (30). Moreover, respiratory or diarrheal syndrome and an altered oral microbiota have been reported as risk 234 235 factors of Noma (14). The HIV/AIDS pandemic increases the number of cases outside the Noma belt region and is considered to be a viable risk factor of the disease (31). Other risk 236 237 factors that have been reported in several articles include the absence of breastfeeding, 238 unsafe drinking water, limited access to high-quality health, and food security (1) (32) (33).

On the other hand, childhood vaccine coverage has been reported as a protective factor not 239 to develop Noma (34). Diarrheal diseases, drinking river water, living with domestic animals, 240 vaccination coverage, and measle, malaria, and helminthic infections were tested for possible 241 significant association with the development of Noma in this study. The findings of this study 242 supported the above argument. In other words, measles, malaria, helminthic infections, 243 diarrheal diseases, presence of domestic animals at home have been identified as potential 244 risk factors to develop Noma among the cases. On the other hand, vaccination coverage has 245 246 shown a statistically significant protective effect not to develop Noma among the controls.

Malnutrition is considered to be an important risk factor for Noma (35) (36). In Africa, most 247 of the cases were reported during the dry season when food is scarce, and when the incidence 248 249 of measles is highest (37). The debilitating diseases such as malaria and measles have shown 250 a statistically significant association of being precursors to Noma in this study. Hence the periodicity of onset of the disease in this study could be explained at the dry seasons as food 251 252 is scarce, and the incidence of measle and malaria often increase (38). Measles and malaria could also be important risk factors because of the associated immunosuppression (39) (40). 253 Furthermore, malnutrition could be regarded as a confounding factor in these associations. 254 However, a further in-depth investigation needs to be carried out. 255

The proportion of vaccination coverage in many developing countries is below the standards recommended by the WHO (41). There is evidence that the occurrence of vaccinepreventable diseases and malnutrition precedes the onset of Noma. The low coverage of vaccination not only increases the risk of morbidity and mortality from vaccine-preventable diseases but is a contributing factor in immunosuppression, which is thought to play a vital role in the sequence of events for Noma development (42). Measle, the only vaccine-

preventable disease that has been identified as a risk factor of Noma in this study, could cause immunosuppression among the cases described (43). The diarrheal and helminthic infections that have been identified in this study could also cause immunosuppression. This immunosuppression could be generally confounded by low coverage of vaccination.

On the contrary, the protective effect of vaccine coverage that has been identified in this study could be regarded as a positive factor to reduce the burden of the disease. Living with domestic animals is found to be the other risk factor of Noma among the cases studied in this study. This factor could be explained in terms of the lack of proper sanitation. On the other hand, drinking river water has shown neither protective nor causative effect on the development of Noma in this study.

The tropical climate, lack of education, rural condition, poor sanitation, and poverty are the leading causes of the high occurrence of Noma (11). A tropical climate characterizes the Afar, Somali, Gambella, Tigray, part of Amhara and Oromia regions. These regions constituted nearly 73% of the total cases admitted to the three Noma treatment facilities in Ethiopia. Climate could be also considered as a potential risk factor for the development of Noma in Ethiopia. Nevertheless, further investigation needs to be carried out.

Furthermore, several studies have shown that in countries where the condition is widespread, risk factors such as malnutrition, debilitating diseases like malaria and measles, close residential proximity to livestock are reported (44) (45). Moreover, respiratory or diarrheal syndrome and an altered oral microbiota have been reported as potential risk factors of Noma. The HIV/AIDS pandemic increases the number of cases outside the Noma belt region and is considered to be a viable risk factor of the disease (46) (47). On the other hand, childhood vaccine coverage has been reported as a protective factor for developing the

condition. Similarly, in this study measles, malaria, and helminthic infections, diarrheal 285 286 diseases, and the presence of domestic animals at home have been identified as potential risk factors to develop Noma among the cases. On the other hand, vaccination coverage has 287 shown a statistically significant protective effect not to develop Noma among the controls. 288 In general, the risk factors of Noma reported in the contemporary literature are highly related 289 290 to poverty (48). In other words, Noma can be considered as an excellent biological parameter 291 of extreme poverty. Hence, policymakers need to be aware that activities against extreme 292 poverty can inevitably avert the occurrence as well as an ill sequela of the disease in developing countries (27). 293

Noma is a disfiguring necrotizing disease of the Oro-facial tissue. It is an "infectious" disease 294 295 of unknown etiology (49). The burden of the disease can be explained through its high mortality rate and psychosocial morbidity (50). Following the devastating facial 296 disfigurements, survivors are often discriminated against from social life (51). Noma survivals 297 298 are often left with devastating orofacial defects, which resembles a dramatic amalgamation 299 of oncologic, congenital, and traumatic deformities (52). For instance, a retrospective study that included 22 Noma cases who undergo surgical intervention in Nigeria has revealed 83.3% 300 301 had lip involvement (53).

302 Conclusions

In conclusion, this study suggests that disadvantaged children under the age of 10 are predominantly affected by the disease. Most of the victims have shown remarkable Nomainduced facial disfigurements, which exposed them to social discrimination and tangible psycho-social crisis. Living with domestic animals, inaccessibility of adequate vaccination coverage, high morbidity of infectious diseases such as measles, malaria, helminths, and
 diarrheal diseases have been identified as potential risk/predisposing factors for Noma in
 Ethiopia. Debilitating conditions, along with malnutrition, can explain the overall risk factors
 identified in this study. Though adequate data on risk factors are still lacking, the information
 obtained from this study underscores that Noma must not be neglected.

312 Noma is a debilitating disease primarily affecting the poor and has been called the "face of poverty." It occurs among the underprivileged society where patients do not have access to 313 314 proper medical care. Poverty, along with low access to health care, can explain the overall risk factors identified in this study. In other words, Noma can be considered as an excellent 315 indicator of extreme poverty. Improving the economic status of the disadvantaged 316 317 communities can be considered as the crucial strategy to eradicate Noma globally. History 318 has revealed that Noma can be completely eradicated by enhancing economic progress and reducing poverty. Therefore, strong socio-economic and health policies need to be developed 319 320 to enable the poorest to afford to acceptable life and access medical care (preventive and surgical rehabilitation), respectively. 321

322 Acknowledgment

I would like to acknowledge with gratitude the School of Global Health and Bioethics at
 EUCLID (Pôle Universitaire EUCLIDE) for supporting the project with useful scientific advice.

325 **References**

Ashok N, Tarakji B, Darwish S, Rodrigues JC, Altamimi MA. A review on noma: a recent
 update. Glob J Health Sci. 2016;8(4):53.

Paster BJ, Falkler Jr WA, Enwonwu CO, Idigbe EO, Savage KO, Levanos VA, et al.
 Prevalent bacterial species and novel phylotypes in advanced noma lesions. J Clin
 Microbiol. 2002 Jun;40(6):2187–91.

- Enwonwu CO. Noma: a neglected scourge of children in sub-Saharan Africa. Bull World
 Health Organ. 1995;73(4):541.
- Giddon DB, Jerome Zackin S, Goldhaber P. Acute necrotizing ulcerative gingivitis in college students. J Am Dent Assoc. 1964 Mar 1;68(3):381–6.
- 335 5. Marck KW. A history of noma, the" Face of Poverty". Plast Reconstr Surg.
 336 2003;111(5):1702-7.
- Microbiological understandings and mysteries of noma (cancrum oris) Falkler 1999 Oral Diseases Wiley Online Library [Internet]. [cited 2022 Mar 21]. Available from:
 https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1601-0825.1999.tb00081.x
- Enwonwu CO, Falkler WA, Idigbe EO, Afolabi BM, Ibrahim M, Onwujekwe D, et al.
 Pathogenesis of cancrum oris (noma): confounding interactions of malnutrition with
 infection. Am J Trop Med Hyg. 1999;60(2):223–32.
- 8. Enwonwu CO. Epidemiological and biochemical studies of necrotizing ulcerative
 gingivitis and noma (cancrum oris) in Nigerian children. Arch Oral Biol.
 1972;17(9):1357–71.
- Bolivar I, Whiteson K, Stadelmann B, Baratti-Mayer D, Gizard Y, Mombelli A, et al.
 Bacterial diversity in oral samples of children in Niger with acute noma, acute
 necrotizing gingivitis, and healthy controls. PLoS Negl Trop Dis. 2012;6(3):e1556.
- Farley E, Mehta U, Srour ML, Lenglet A. Noma (cancrum oris): A scoping literature
 review of a neglected disease (1843 to 2021). Vinetz JM, editor. PLoS Negl Trop Dis.
 2021 Dec 14;15(12):e0009844.
- Farley E, Lenglet A, Ariti C, Jiya NM, Adetunji AS, van der Kam S, et al. Risk factors for
 diagnosed noma in northwest Nigeria: A case-control study, 2017. PLoS Negl Trop Dis.
 2018;12(8):e0006631.
- Tonna JE, Lewin MR, Mensh B. A case and review of noma. PLoS Negl Trop Dis.
 2010;4(12):e869.
- Baratti-Mayer D, Gayet-Ageron A, Hugonnet S, François P, Pittet-Cuenod B, Huyghe A,
 et al. Risk factors for noma disease: a 6-year, prospective, matched case-control study
 in Niger. Lancet Glob Health. 2013;1(2):e87–96.
- Braimah RO, Adeniyi AS, Taiwo AO, Ibikunle AA, Gbotolorun OM, Aregbesola SB, et al.
 Risk Factors and Mortality Rate of Acute Cancrum Oris (noma) in Sokoto North-West
 Nigeria: A 13-year Survey. 2017;

Whiteson KL, Lazarevic V, Tangomo-Bento M, Girard M, Maughan H, Pittet D, et al.
 Noma affected children from Niger have distinct oral microbial communities based on
 high-throughput sequencing of 16S rRNA gene fragments. PLoS Negl Trop Dis. 2014
 Dec;8(12):e3240.

- 16. D'Agostino FJ. A review of noma: Report of a case treated with aureomycin. Oral Surg
 Oral Med Oral Pathol. 1951;4(8):1000–6.
- 17. Koech KJ. Cancrum oris in an adult with human immunodeficiency virus infection: case
 report. East Afr Med J. 2010;87(1):38–40.
- 18. Lembo S, Leonibus CD, Francia MG, Lembo C, Ayala F. Cancrum oris in a boy with Down
 syndrome. J Am Acad Dermatol. 2011 Jun 1;64(6):1200–2.
- van Niekerk C, Khammissa RAG, Altini M, Lemmer J, Feller L. Noma and cervicofacial
 necrotizing fasciitis: clinicopathological differentiation and an illustrative case report of
 noma. AIDS Res Hum Retroviruses. 2014 Mar;30(3):213–6.
- Vaidyanathan S, Tullu MS, Lahiri KR, Deshmukh CT. Pseudomonas sepsis with Noma: an
 association? Indian J Med Sci. 2005 Aug;59(8):357–60.
- Hartman EHM, Damme PAV, Rayatt S, Kuokkanen HOM. Return of the Waltzing Flap in
 Noma Reconstructive Surgery: Revisiting the Past in Difficult Circumstances. J Plast
 Reconstr Aesthet Surg. 2010 Jan 1;63(1):e80–1.
- Temporal relationship between the occurrence of fresh noma and the timing of linear
 growth retardation in Nigerian children Enwonwu 2005 Tropical Medicine & amp;
 International Health Wiley Online Library [Internet]. [cited 2022 Mar 17]. Available
 from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-3156.2004.01351.x
- Srour ML, Watt B, Phengdy B, Khansoulivong K, Harris J, Bennett C, et al. Noma in Laos:
 stigma of severe poverty in rural Asia. Am J Trop Med Hyg. 2008;78(4):539–42.
- 24. Marck KW. Noma: a neglected enigma. Lancet Glob Health. 2013;1(2):e58–9.
- 388 25. Berthold P. Noma: a forgotten disease. Dent Clin. 2003;47(3):559–74.
- Farley E, Ariti C, Amirtharajah M, Kamu C, Oluyide B, Shoaib M, et al. Noma, a
 neglected disease: A viewpoint article. PLoS Negl Trop Dis. 2021 Jun
 17;15(6):e0009437.
- 392 27. Maley A, Desai M, Parker S. Noma: A disease of poverty presenting at an urban hospital
 393 in the United States. JAAD Case Rep. 2015;1(1):18–20.
- 28. Ogbureke KU, Ogbureke EI. NOMA: a preventable "scourge" of African children. Open
 Dent J. 2010;4:201.
- Hotez PJ. Forgotten people, forgotten diseases: the neglected tropical diseases and
 their impact on global health and development. John Wiley & Sons; 2021.

398 30. Speiser S, Langridge B, Birkl MM, Kubiena H, Rodgers W. Update on Noma: systematic
399 review on classification, outcomes and follow-up of patients undergoing reconstructive
400 surgery after Noma disease. BMJ Open. 2021;11(8):e046303.

- Brady-West DC, Richards L, Thame J, Moosdeen F, Nicholson A. Cancrum oris (noma) in
 a patient with acute lymphoblastic leukaemia. A complication of chemotherapy
 induced neutropenia. West Indian Med J. 1998;47(1):33–4.
- 32. Srour ML, Baratti-Mayer D. Why is noma a neglected-neglected tropical disease? PLoS
 Negl Trop Dis. 2020 Aug 20;14(8):e0008435.
- 33. Dominic C, Farley E, Elkheir N. More than 100 years of neglect: a bibliometric analysis
 of global research on noma (cancrum oris). Trans R Soc Trop Med Hyg. 2021;
- Ahlgren M, Funk T, Marimo C, Ndiaye C, Alfvén T. Management of noma: practice
 competence and knowledge among healthcare workers in a rural district of Zambia.
 Glob Health Action. 2017;10(1):1340253.
- 411 35. Srour ML, Marck K, Baratti-Mayer D. Noma: Overview of a Neglected Disease and
 412 Human Rights Violation. Am J Trop Med Hyg. 2017 Feb 8;96(2):268–74.
- 36. Weledji EP, Njong S. Cancrum Oris (Noma): The Role of Nutrition in Management. J Am
 Coll Clin Wound Spec. 2016 Aug 12;7(1–3):50–2.
- 37. Sophie H, Thomas F, Jürg U. Noma: epidemiology and global burden of a neglected
 disease. ISEE Conf Abstr [Internet]. 2013 Sep 19 [cited 2022 Mar 21]; Available from:
 https://ehp.niehs.nih.gov/doi/abs/10.1289/isee.2013.P-1-14-13
- 418 38. Yuca K, Yuca SA, Cankaya H, Caksen H, Calka O, Kiriş M. Report of an infant with noma
 419 (cancrum oris). J Dermatol. 2004 Jun;31(6):488–91.
- 420 39. Pedro K, Smit DA, Morkel JA. Cancrum Oris (noma) in an HIV-positive adult: A case
 421 report and literature review. South Afr Dent J. 2016 Jul;71(6):248–52.
- 40. Costini B, Larroque G, Duboscq JC, Montandon D. [Noma or cancrum oris:
 etiopathogenic and nosologic aspects]. Med Trop (Mars). 1995 Jan 1;55(3):263–73.
- 424 41. Immunization coverage [Internet]. [cited 2022 Mar 24]. Available from:
 425 https://www.who.int/news-room/fact-sheets/detail/immunization-coverage
- 42. Tall F, Ki-Zerbo G, Ouedraogo I, Guigma Y. [Noma in children in a hospital environment
 in Bobo-Dioulasso: epidemiologic, clinical and management aspects]. Odonto-Stomatol
 Trop Trop Dent J. 2001 Dec;24(96):21–5.
- 43. Lazarus D, Hudson DA. Cancrum oris a 35-year retrospective study. S Afr Med J
 430 [Internet]. 1997 [cited 2022 Mar 24];87(10). Available from:
- 431 https://www.ajol.info/index.php/samj/article/view/157394

- 432 44. Rowe D, McKerrow N, Uys A, Winstanley T. Case Study: Cancrum oris (noma) in a
 433 malnourished HIV-positive child from rural Kwazulu-Natal. South Afr J HIV Med.
 434 2004;5(3):45–6.
- 435 45. Kaimudin A, Hidajah AC. EPIDEMIOLOGICAL INVESTIGATION OF NOMA IN PAPUA
 436 PROVINCE IN 2017. J Berk Epidemiol. 2020 Jan 28;8(1):16–25.
- 437 46. Ki-Zerbo GA, Guigma Y. [Noma and HIV infection: apropos of a case at the National
 438 Hospital Center in Bobo-Dioulasso (Burkina Faso). Odonto-Stomatol Trop Trop Dent J.
 439 2001 Dec 1;24(96):26–9.
- 47. Prado-Calleros HM, Castillo-Ventura BB, Jiménez-Escobar I, Ramírez-Hinojosa JP, LópezGómez A, García-de-la-Cruz M, et al. Noma and Noma-like disease in HIV/AIDS
 patients, a comorbid interaction: A systematic review: J Infect Dev Ctries. 2018 Feb
 28;12(02):89–96.
- 444 48. Jain A, Ranka R. The real face of "face of poverty": an insight on noma. Hosp Palliat
 445 Med Int J. 2017;1(2):49–52.
- 446 49. Baratti-Mayer D, Pittet B, Montandon D, Bolivar I, Bornand J-E, Hugonnet S, et al.
 447 Noma: an "infectious" disease of unknown aetiology. Lancet Infect Dis. 2003;3(7):419–
 448 31.
- 50. Srour ML, Marck K, Baratti-Mayer D. Noma: overview of a neglected disease and
 human rights violation. Am J Trop Med Hyg. 2017;96(2):268.
- 451 51. Rickart AJ, Rodgers W, Mizen K, Merrick G, Wilson P, Nishikawa H, et al. Facing Africa:
 452 describing noma in Ethiopia. Am J Trop Med Hyg. 2020;103(2):613.
- Issa AH, Ousmane KAK, Issa EOH, Shen J, Douma MD, Ibrahim AS, et al. Influencing
 Factors for Social Acceptance of Noma (Cancrum Oris) Patients in Niger: A Hospital
 Based Retrospective Study [Internet]. Rochester, NY: Social Science Research Network;
 2021 Jul [cited 2022 Mar 24]. Report No.: ID 3878080. Available from: https://papers.ssrn.com/abstract=3878080
- 458 53. Adeniyi SA, Awosan KJ. Pattern of Noma (Cancrum Oris) and Its Risk Factors in
 459 Northwestern Nigeria: A Hospital-Based Retrospective Study. Ann Afr Med.
 460 2019;18(1):17–22.

461

463 Appendices

464 Appendix S1: Case Report Form

Heron Gezahegn Gebretsadik, EUCLID UNIVERSITY, Epidemiology of Noma/Cancrum Oris in Ethiopia							
Subject Initials Subje	ect ID Dat	e:// Month Day Year					
	Demographics						
Subject Medical Record Number*:							
First Name*: Middle Name (or initial): Last Name*:							
Birthdate*: Month / Day /	Year						
Gender*: (check one) Male Female Unknown or Not Reported	Male Ethiopian Female Non-Ethiopian						
Race*: (check all that apply) Cromo Amhara Somali	☐ Tigray ☐ Sidama ☐ Other						
Other Medical Record Number(s): Medical Record Number Ho	ospital/Care Provider (e.g. VA Hosp	ital, Meriter Hospital, EPIC)					
Contact Information: Address: City: Phone Number: Home Work Cell Other	State: Alternate Phone Number: Home Work Cell Other	Unit #: Zip: Email address:					
Preferred method of contact: Emergency Contact:							
Name: Address: City: Phone Number: Home Work Cell Other	State: Alternate Phone Number: Home Work Cell Other	Unit #: Zip: Email address:					
Preferred method of contact: *indicates required field							
Form Completed By:		Date:					

Heron Gezahegn Gebretsadik, EUCLID UNIVERSITY, Epidemiology of Noma/Cancrum Oris in Ethiopia

Subject Initials		Subject ID]	Date:			/			/		
							Мо	nth		Da	y		Y	ear

Clinical Information (Noma/Cancrum Oris)									
Body Involved	Diagnosed condition?	Diagnosis/Condition/Surgery	Onset Date Or Year	Prognosi s/Healing Status, Healed?					
[Upper Lip]	Yes No			Yes No					
[Lower Lip]	☐ Yes ☐ No			Yes No					
[Both Lips]	☐ Yes ☐ No			Yes No					
[Unilateral]	Yes No			Yes No					
[Bilateral]	Yes No			Yes No					
[Gingiva+Mucosa/AN UG]	Yes No			Yes No					
[Lower Face (Lips, Lower Cheeks, Jawline, Mandible)]	□ Yes □ No			Yes No					
[Mid Face (TMJ, Nasal, Zygoma, Oral Commissure, Maxilla, Infra Orbital Margin)]	☐ Yes ☐ No			□ Yes □ No					
[Mid & Lower Face]	Yes No			Yes No					
[Upper Face (Brow, Upper lid)]	Yes No			Yes No					
[Related ADL Limitations]	☐ Yes ☐ No			Yes No					
Other (specify)	☐ Yes ☐ No			Yes No					

ADDITIONAL NOTES:

Clinical Data Not Obtained

MEDICAL HISTORY OBTAINED BY:

466

467 Appendix S2: Questionnaire

QUESTIONNAIRE

Heron Gezahegn Gebretsadik, EUCLID UNIVERSITY, Epidemiology and Risk Factors of Noma, in Ethiopia.

Date of interview (DD/MM/YYYY): ____/____

Interviewer:

IDENTIFICATION: STUDY PARTICIPANT

Initials (sumame/first name) I___I

1) DEMOGRAPHICS OF PARTICIPANT

Sex: 🗆 Male 🛛 Female

Date of birth: ____ / ___ / ____

Age at development of Noma: _____ years

Area of residence: _____

2) MEDICAL HISTORY

The following questions aim to collect information on past medical history that could potentially related to Noma.

Participant has previously had Noma:

If yes, specify date:

□Yes □No

__/__/

Family history of Noma:

- If yes, specify who and date:

🗆 Yes 🗆 No 🗆 Unknown

__/__/ ____

History of other oral health issues:

- If yes, specify condition and date:

🗆 Yes 🗆 No 🗆 Unknown

__/__/

History of diarrheal diseases:

- If yes, specify date and duration:

🗆 Yes 🗆 No 🗆 Unknown

__/__/

History of helminthic infection:

- If yes, specify date and duration:

🗆 Yes 🗆 No 🗆 Unknown

__/__/

History of malaria infection:

- If yes, specify date and duration:

🗆 Yes 🗆 No 🗆 Unknown

__/__/

History of measle infection:

- If yes, specify date and duration:

🗆 Yes 🗆 No 🗆 Unknown

__/__/

Other medical history:

- If yes, specify condition and duration:

🗆 Yes 🗆 No 🗆 Unknown

Surgical history:

- If yes, specify:

🗆 Yes 🗆 No 🗆 Unknown

History of childhood vaccination:

- If yes, specify date:

- If yes, indicate:

🗆 Yes 🗆 No 🗆 Unknown

___/___/____

 \Box Information verified on vaccine card \Box Information provided verbally

3) EXPOSURE

History of living with domestic animals:

- If yes, specify date and duration:

🗆 Yes 🗆 No 🗆 Unknown

__/__/

History of drinking river water:

- If yes, specify date and duration:

🗆 Yes 🗆 No 🗆 Unknown

___/___/